KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2016; Announces Dividend Second Quarter Ended September 30, 2016, Payable December 5, 2016 and Provides Dividend Guidance for the Year Ending March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2017
November 07, 2016
Share
KYORIN Holdings, Inc. reported consolidated earnings results for the six months ended September 30, 2016. For the period, the company reported net sales of ¥54,628 million compared to ¥52,386 million, operating income of ¥3,663 million compared to ¥4,099 million, ordinary income of ¥3,921 million compared to ¥4,266 million, profit attributable to owners of parent income of ¥2,684 million or ¥36.56 per share compared to ¥2,967 million or ¥40.10 per share for the last year.
The company announced dividend for the second quarter ended September 30, 2016 of ¥20.00 per share compared to ¥20.00 per share paid in last year. The dividend is payable December 5, 2016.
The company provided dividend guidance of ¥38.00 per share for the year ending March 31, 2017 compared to ¥38.00 per share paid in last year.
The company provided earnings guidance for the year ending March 31, 2017. For the year, the company expected net sales of ¥120,000 million, operating income of ¥14,500 million, ordinary income of ¥14,900 million and profit attributable to owners of parent income of ¥10,700 million or ¥145.23 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2016; Announces Dividend Second Quarter Ended September 30, 2016, Payable December 5, 2016 and Provides Dividend Guidance for the Year Ending March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2017
KYORIN PHARMACEUTICAL CO., LTD. 
